591 related items for PubMed ID: 31899532
1. Comparison of Risk of Recrudescent Fever in Children With Kawasaki Disease Treated With Intravenous Immunoglobulin and Low-Dose vs High-Dose Aspirin.
Platt B, Belarski E, Manaloor J, Ofner S, Carroll AE, John CC, Wood JB.
JAMA Netw Open; 2020 Jan 03; 3(1):e1918565. PubMed ID: 31899532
[Abstract] [Full Text] [Related]
2. Treatment of acute Kawasaki disease: aspirin's role in the febrile stage revisited.
Hsieh KS, Weng KP, Lin CC, Huang TC, Lee CL, Huang SM.
Pediatrics; 2004 Dec 03; 114(6):e689-93. PubMed ID: 15545617
[Abstract] [Full Text] [Related]
3. Low-dose or no aspirin administration in acute-phase Kawasaki disease: a meta-analysis and systematic review.
Chiang MH, Liu HE, Wang JL.
Arch Dis Child; 2021 Jul 03; 106(7):662-668. PubMed ID: 33172886
[Abstract] [Full Text] [Related]
4. Early treatment with intravenous immunoglobulin in patients with Kawasaki disease.
Tse SM, Silverman ED, McCrindle BW, Yeung RS.
J Pediatr; 2002 Apr 03; 140(4):450-5. PubMed ID: 12006960
[Abstract] [Full Text] [Related]
5. Efficacy between low and high dose aspirin for the initial treatment of Kawasaki disease: Current evidence based on a meta-analysis.
Zheng X, Yue P, Liu L, Tang C, Ma F, Zhang Y, Wang C, Duan H, Zhou K, Hua Y, Wu G, Li Y.
PLoS One; 2019 Apr 03; 14(5):e0217274. PubMed ID: 31117119
[Abstract] [Full Text] [Related]
6. Corticosteroids for the treatment of Kawasaki disease in children.
Wardle AJ, Connolly GM, Seager MJ, Tulloh RM.
Cochrane Database Syst Rev; 2017 Jan 27; 1(1):CD011188. PubMed ID: 28129459
[Abstract] [Full Text] [Related]
7. Different dose aspirin plus immunoglobulin (DAPI) for prevention of coronary artery abnormalities in Kawasaki disease: Study protocol for a multi-center, prospective, randomized, open-label, blinded end-point, non-inferiority trial.
Wu Y, Hu L, Xie X, Li W, Wang Y, Zhang L, Huang P, Li F, Li J, Xia S, Yuan J, Li M, Wang Z, Zhang X.
Am Heart J; 2024 Jul 27; 273():1-9. PubMed ID: 38508571
[Abstract] [Full Text] [Related]
8. Timing of intravenous immunoglobulin treatment and risk of coronary artery abnormalities in children with Kawasaki disease.
Bal AK, Prasad D, Umali Pamintuan MA, Mammen-Prasad E, Petrova A.
Pediatr Neonatol; 2014 Oct 27; 55(5):387-92. PubMed ID: 24636168
[Abstract] [Full Text] [Related]
9. Clinical and epidemiological characteristics of children with Kawasaki disease in Turkey.
Ozdemir H, Ciftçi E, Tapisiz A, Ince E, Tutar E, Atalay S, Dogru U.
J Trop Pediatr; 2010 Aug 27; 56(4):260-2. PubMed ID: 20007257
[Abstract] [Full Text] [Related]
10. Coronary Artery Complication in Kawasaki Disease and the Importance of Early Intervention : A Systematic Review and Meta-analysis.
Chen S, Dong Y, Kiuchi MG, Wang J, Li R, Ling Z, Zhou T, Wang Z, Martinek M, Pürerfellner H, Liu S, Krucoff MW.
JAMA Pediatr; 2016 Dec 01; 170(12):1156-1163. PubMed ID: 27749951
[Abstract] [Full Text] [Related]
11. Infliximab for intensification of primary therapy for Kawasaki disease: a phase 3 randomised, double-blind, placebo-controlled trial.
Tremoulet AH, Jain S, Jaggi P, Jimenez-Fernandez S, Pancheri JM, Sun X, Kanegaye JT, Kovalchin JP, Printz BF, Ramilo O, Burns JC.
Lancet; 2014 May 17; 383(9930):1731-8. PubMed ID: 24572997
[Abstract] [Full Text] [Related]
12. High-Dose Aspirin is Associated with Anemia and Does Not Confer Benefit to Disease Outcomes in Kawasaki Disease.
Kuo HC, Lo MH, Hsieh KS, Guo MM, Huang YH.
PLoS One; 2015 May 17; 10(12):e0144603. PubMed ID: 26658843
[Abstract] [Full Text] [Related]
13. Aspirin Dose in Kawasaki Disease: The Ongoing Battle.
Dhanrajani A, Chan M, Pau S, Ellsworth J, Petty R, Guzman J.
Arthritis Care Res (Hoboken); 2018 Oct 17; 70(10):1536-1540. PubMed ID: 29287309
[Abstract] [Full Text] [Related]
14. High-dose versus low-dose intravenous immunoglobulin for treatment of children with Kawasaki disease weighing 25 kg or more.
Suzuki T, Michihata N, Yoshikawa T, Hata T, Matsui H, Fushimi K, Yasunaga H.
Eur J Pediatr; 2020 Dec 17; 179(12):1901-1907. PubMed ID: 32862279
[Abstract] [Full Text] [Related]
15. Effect of different doses of aspirin on the prognosis of Kawasaki disease.
Wang J, Chen H, Shi H, Zhang X, Shao Y, Hang B, Xu Z, Rong X, Chu M, Qiu H.
Pediatr Rheumatol Online J; 2020 Jun 11; 18(1):48. PubMed ID: 32527316
[Abstract] [Full Text] [Related]
16. Aspirin Dose and Prevention of Coronary Abnormalities in Kawasaki Disease.
Dallaire F, Fortier-Morissette Z, Blais S, Dhanrajani A, Basodan D, Renaud C, Mathew M, De Souza AM, Dionne A, Blanchard J, Saulnier H, Kaspy K, Rached-d'Astous S, Dahdah N, McCrindle BW, Human DG, Scuccimarri R.
Pediatrics; 2017 Jun 11; 139(6):. PubMed ID: 28562282
[Abstract] [Full Text] [Related]
17. Coronary risk factors in Kawasaki disease treated with additional gammaglobulin.
Miura M, Ohki H, Tsuchihashi T, Yamagishi H, Katada Y, Yamada K, Yamashita Y, Sugaya A, Komiyama O, Shiro H.
Arch Dis Child; 2004 Aug 11; 89(8):776-80. PubMed ID: 15269082
[Abstract] [Full Text] [Related]
18. High-dose aspirin for Kawasaki disease: outdated myth or effective aid?
Amarilyo G, Koren Y, Brik Simon D, Bar-Meir M, Bahat H, Helou MH, Mendelson A, Hezkelo N, Chodick G, Berkun Y, Eisenstein E, Butbul Aviel Y, Barkai G, Bolkier Y, Padeh S, Brik R, Hashkes PJ, Harel L, Uziel Y.
Clin Exp Rheumatol; 2017 Aug 11; 35 Suppl 103(1):209-212. PubMed ID: 28079513
[Abstract] [Full Text] [Related]
19. Comparison of high-dose and low-dose aspirin plus intravenous immunoglobulin in the treatment of Kawasaki syndrome.
Saulsbury FT.
Clin Pediatr (Phila); 2002 Oct 11; 41(8):597-601. PubMed ID: 12403377
[Abstract] [Full Text] [Related]
20. Randomized trial of pulsed corticosteroid therapy for primary treatment of Kawasaki disease.
Newburger JW, Sleeper LA, McCrindle BW, Minich LL, Gersony W, Vetter VL, Atz AM, Li JS, Takahashi M, Baker AL, Colan SD, Mitchell PD, Klein GL, Sundel RP, Pediatric Heart Network Investigators.
N Engl J Med; 2007 Feb 15; 356(7):663-75. PubMed ID: 17301297
[Abstract] [Full Text] [Related]
Page: [Next] [New Search]
